Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.
Assistant Professor Kathy Vu, BSc (Pharm), PharmD highlights biosimilar education initiatives undertaken by the Leslie Dan Faculty of Pharmacy at the University of Toronto in this Biosimilars in Oncology - Winter 2021 article. Posted with permission of Catalytic Health.
Dorothy Lo, MD and Ivan Tyono, BSc (Pharm), RPh review the frameworks and priorities for supporting biosimilar adoption in Canada in this Biosimilars in Oncology - Winter 2021 article. Posted with permission of Catalytic Health.
Nedzad Pojskic of Green Shield Canada detailed why payers should become bigger advocates for biosimilar uptake at a recent Festival of Biologics conference. Report by The Center for Biosimilars.
Benefits Canada coverage of the webinar “Evidence to Policy —Biosimilar Transitioning in Canada”.
Almost 6,000 patients on biologic drug Humira adalimumab will be switched to an adalimumab biosimilar over a six-month period.
Health Insight article on the Canadian experience of switching to biosimilars. "…there are many studies and real-world patient data showing that the outcomes are the same when people are switched, including in Europe, and in parts of Canada. Switching to a biosimilar shouldn’t be something for patients to fear," says rheumatologist Dr. Janet Pope.